Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned a consensus recommendation of "Buy" from the nine research firms that are covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $7.43.

TRVI has been the subject of a number of analyst reports. Leerink Partnrs raised shares of Trevi Therapeutics to a "strong-buy" rating in a report on Monday, September 9th. HC Wainwright initiated coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They issued a "buy" rating and a $6.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday, October 4th. B. Riley reissued a "buy" rating and issued a $6.00 price objective on shares of Trevi Therapeutics in a report on Monday, October 7th. Finally, EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a "strong-buy" rating in a report on Monday, August 19th.

Insiders Place Their Bets

In other news, insider Thomas Sciascia sold 18,660 shares of the firm's stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the transaction, the insider now owns 220,315 shares of the company's stock, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Thomas Sciascia sold 18,660 shares of the firm's stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $2.76, for a total value of $51,501.60. Following the completion of the transaction, the insider now owns 220,315 shares of the company's stock, valued at approximately $608,069.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Jennifer L. Good sold 10,981 shares of the firm's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares of the company's stock, valued at approximately $644,205.26. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,355 shares of company stock valued at $116,663 over the last 90 days. 24.37% of the stock is owned by company insiders.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently added to or reduced their stakes in TRVI. Ally Bridge Group NY LLC acquired a new stake in Trevi Therapeutics in the second quarter valued at approximately $4,395,000. Logos Global Management LP raised its holdings in Trevi Therapeutics by 27.3% during the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company's stock worth $8,344,000 after purchasing an additional 600,000 shares in the last quarter. Rosalind Advisors Inc. raised its holdings in Trevi Therapeutics by 50.3% during the second quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company's stock worth $4,147,000 after purchasing an additional 465,561 shares in the last quarter. Propel Bio Management LLC purchased a new stake in shares of Trevi Therapeutics during the 1st quarter worth approximately $897,000. Finally, Opaleye Management Inc. boosted its holdings in shares of Trevi Therapeutics by 4.3% in the 1st quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company's stock valued at $9,125,000 after buying an additional 110,000 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company's stock.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI remained flat at $3.12 during mid-day trading on Friday. 290,212 shares of the stock were exchanged, compared to its average volume of 260,335. The business has a fifty day simple moving average of $3.08 and a 200-day simple moving average of $2.89. The firm has a market cap of $219.76 million, a PE ratio of -9.18 and a beta of 0.97. Trevi Therapeutics has a 1-year low of $0.97 and a 1-year high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). During the same quarter last year, the business posted ($0.07) EPS. As a group, equities analysts predict that Trevi Therapeutics will post -0.47 EPS for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.